Compare Planet Labs (PL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Planet Labs vs Repligen Corporation Common Stock — how do they compare? Planet Labs trades at $13.77 (market cap $5.52B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 2× Planet Labs's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Planet Labs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Planet Labs for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| PL | RGEN | |
|---|---|---|
Market Cap | $5.52B | $11.14B |
Volume | 10,123,547 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $51.40 | $194.57 |
52-Week Low | $11.16 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.15B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Planet Labs (PL) trades at $15.16, down 5.01% on the day, reflecting ongoing bearish technical pressure despite recent satellite launches and government contract wins. The company shows revenue growth potential with $378 million projected for 2026, but faces significant profitability challenges with a -95.13% net income margin and negative ROE of -71.97%. Analyst sentiment remains positive with 13 buy ratings and a $32.50 consensus price target, though technical indicators signal bearish momentum.
The stock presents a high-risk opportunity with substantial upside potential if execution improves, but current financial performance and bearish technicals warrant caution. Key catalysts include defense contract execution and satellite deployment success, while risks include persistent losses, competitive pressure from SpaceX, and valuation concerns at current P/S of 13.35.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Planet Labs
Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
